Close menu




December 1st, 2020 | 09:54 CET

Desert Gold, BioNTech, Vodafone - Healthier, Cleaner, Gold!

  • Investments
Photo credits: pixabay.com

Asian stocks have recently faltered near their record highs, but the Nikkei, in particular, has experienced a grand rally of 15% in the last 4 weeks. Yesterday 30.11. is a popular settlement day for fund managers around the globe because from this date on you only have 1 month to clean the portfolio from unwanted components. In simple terms, stocks which ran poorly all year are likely to be sold and stocks that everyone's talking about and have performed well so far, tend to be topped up again. Among asset management experts, these measures are called "window dressing", i.e., perfecting the design of the viewing rooms in the form of a portfolio listing.

On the market as a whole, investors seem to be developing the view that the economic recovery will gain momentum next year, and this is driving some to liquidate their gold holdings - intended as a security investment - rather than to sell them. On the technical front, support for gold remains intact at around USD 1,750 to USD 1,770 an ounce. Silver continues to see massive interest near the psychological level of USD 22-23, the Technical Analysis tells us. Whether we can take this as a given at the end of the year remains to be seen; the pressure on precious metals prices is currently high.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: CA25039N4084 , US09075V1026 , GB00BH4HKS39

Table of contents:


    Desert Gold - The Africa fantasy remains

    Although the Desert Gold stock has been quiet in recent weeks, preparations for a new exploration program are in full swing. The funds from the last transaction are still available with traded prices of well over CAD 0.30. A capital increase at CAD 0.28 could be placed, and CAD 6.5 million could be raised.

    The company is surrounded by big names like B2Gold and Barrick Gold. West Africa is the place to be for exploration and production. The huge upside potential for discoveries makes Mali very attractive for junior exploration companies like Desert Gold. The team already explored gold in the past and knows where to drill in the upcoming program. With the money in the bank, the company is very flexible and can focus on increasing the gold reserves.

    At the current price of CAD 0.14, the most recently depressed value has a capitalization of only CAD 18.5 million. Chart Technically, one is here broadly supported, but at present the tax loss realizations customary in Canada, dominate. In our view, there is, therefore, a clear chance of doubling in the next gold rebound.

    BioNTech - December is the time

    The UK is on the verge of becoming the first country to approve the Covid-19 vaccine from Pfizer Inc. and BioNTech SE, ahead of a long line of countries waiting for protection against the coronavirus. The release is possible as early as the beginning of December, said a person familiar with the situation who asked not to be revealed, as the process is still highly confidential. Earlier last week, the Health Commission MHRA announced that it now has the data it needs to release the vaccine. Nevertheless, the studies will continue to gradually increase their validity, thus documenting the thoroughness of further review.

    The vaccine was already 95% effective in a clinical study involving almost 44,000 people, and so far, there have been no significant safety problems. The first vaccines to a broader audience are likely to be administered as of December 7, the Financial Times reported.

    The UK has ordered enough doses of the Pfizer BioNTech dual-dose vaccine to immunize 20 million people, although this amount will almost certainly not be available immediately. The two Companies responsible have also signed contracts to supply hundreds of millions of vaccines to Europe, the US, Japan and other countries.

    Pfizer-BioNTech's vaccine has moved to the top of the field after delays in testing a vaccine from AstraZeneca Plc and the University of Oxford. Another vaccine from Moderna Inc. has also proven its high efficacy in trials.

    The BioNTech share was recently able to advance several times into the region of USD 120. With a capitalization of USD 25 billion for a product, one wonders whether all fantasy is not already priced in - but after all, the high volatility of the share not only offers investors fun but is also suitable for every gambler. BioNTech has already increased sixfold in 2020.

    Vodafone - Clean radio here

    Vodafone PLC announced a voluntary commitment to reduce global carbon emissions to zero by 2040. By 2030, Vodafone will already have eliminated all emissions from its own activities and from the energy mix it uses, after which the issues of waste avoidance and business travel will be on the agenda. Such green statements are a rarity from the telecommunications industry. After all, what destroys the environmental image more than the radio masts placed arbitrarily in the landscape, which will soon be chasing lush 5G frequencies into the ether. A fancy future design of these masts has not been sighted yet.

    The telecommunications giant said these targets have been endorsed by the Science-Based Targets initiative, supported by the United Nations and WWF, among others, and are consistent with the reductions needed to keep global warming at 1.5°C, the most ambitious goal of the Paris Accord. As early as July 2021, Vodafone's European network will be powered 100% by renewable energy sources, creating a green gigabit network for customers in the 11 target markets, which will grow sustainably and use electricity sources exclusively from wind, solar or hydropower.

    The underlying strategy is obvious: ESG pressure is very high among Vodafone's customers and not least, among the telecommunications giants themselves, to switch their traditional business model to a sustainable one. The measure that immediately comes to mind is, of course, electricity consumption. Thanks to the sustainable changes in Vodafone's strategy, its customers can already take on all the upfront costs of using the service provider and then slide up the ESG scale as well.

    So the Board of Management naturally, proudly and politically correct announces: "Vodafone will also enable our customers to reduce their ecological footprint by using our services, including the Internet of Things". Bravo - we investors are pleased to hear that! Now Vodafone, too, is gaining access to the modern ESG portfolios of sustainably oriented major investors.

    The market capitalization of Vodafone PLC is currently GBP 33.5 billion, but high debt remains a problem. On the charts, the share price has already sent out very positive signals with an increase of 19% since the end of October.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Stefan Feulner on October 4th, 2022 | 11:59 CEST

    RWE, Pathfinder Ventures, United Internet - Panic as an opportunity

    • Camping
    • Investments

    Last week, the crash prophets crawled out of their caves and outdid themselves with forecasts reaching the Corona lows at around 8,000 points in the leading German DAX index. Without a doubt, the general conditions for a sustained stock rally are moderate with the escalation of the Ukraine situation and concerns about further interest rate hikes. Nevertheless, there are attractive entry opportunities at the current level, which could pay off in cash in the long term.

    Read

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read